Abstract 1741P
Background
Little research has been made on real-world clinical scenarios of potential ethical relevance in specific cancers, including sarcomas.
Methods
Our sarcoma multidisciplinary tumor board (MTB) discusses all cases of adult patients with soft tissue sarcomas, bone sarcomas and GIST selected by the clinical oncologist in charge as deserving a multidisciplinary discussion. Over a 1-yr interval, all discussed cases were filtered by a group of senior and junior experts in bioethics and sarcomas in order to highlight those of potential ethical concern, i.e. whenever a problematic conflict could be envisaged between the ethical principles of beneficence, non-maleficence, autonomy and justice. These cases were retrospectively reviewed, and an attempt was made to group them into distinct ethical scenarios.
Results
From January to December 2023, 327 sarcoma cases were discussed by our MTB. Forty-one cases (12%) were prospectively or retrospectively selected as carrying possible ethical relevance. Among them, the following clinical scenarios were identified (total >100% since scenarios are not mutually exclusive): 1. ethically-relevant uncertainty about a diagnostic/treatment option (46%); 2. best treatment option at a high-risk of complications of problematic acceptance (5%); 3. controversial futility (17%); 4. problematic trade-off between quality and quantity of life (17%); 5. problematic management of patient dissent (15%); 6. clinical disagreement of potential ethical concern (10%); 7. problematic communication of all clinical implications to the individual patient (15%). 8. controversial enrolment of an eligible patient in a clinical trial or trial requirements of ethical concern in the individual patient (2%); 9. best clinical option conflicting with social/economical constraints (0.3%); 10. bedside rationing, or perception of implicit rationing of scarce resources (2%).
Conclusions
A non-negligible incidence of ethically-relevant clinical cases was observed. Sarcoma centres should be aware of specific ethical implications possibly affecting their everyday practice. Paradigmatic clinical cases for each of the ten clinical scenarios proposed herein will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1730P - Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
Presenter: NingNing Lu
Session: Poster session 06
Resources:
Abstract
1731P - Phase II study of the CDK2/4/6 inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS)
Presenter: Jing Chen
Session: Poster session 06
1732P - Primary pulmonary sarcoma: A EURACAN project
Presenter: Stephane Collaud
Session: Poster session 06
1733P - Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma
Presenter: Neal Chawla
Session: Poster session 06
1734P - Evaluation of nivolumab in cutaneous angiosarcoma management: The ANGIOCHECK study
Presenter: Yasuhiro Fujisawa
Session: Poster session 06
1735P - Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
Presenter: Zengjun Liu
Session: Poster session 06
Resources:
Abstract
1736P - An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)
Presenter: Edmund Bartlett
Session: Poster session 06
1737P - A comparison of the risk prediction models sarculator and PERSARC in patients with localized soft tissue sarcoma of the extremities and trunk wall
Presenter: Marthe Kobbeltvedt
Session: Poster session 06
1738P - Results from the conference on challenges in sarcoma (CCS) 2024
Presenter: Christian Rothermundt
Session: Poster session 06
1739P - Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part
Presenter: Erlinda Gordon
Session: Poster session 06